Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
12 March 2024 - 11:00PM
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology
company seeking to develop and commercialize universal-RAS/RAF
medicines for broad populations of cancer patients, today announced
the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO
and Founder of ChemoCentryx before its acquisition by Amgen, to its
Board of Directors.
“On behalf of the entire Immuneering team, we
are honored to welcome Dr. Schall to our Board,” said Ben Zeskind,
Chief Executive Officer, Immuneering Corporation. “Tom’s extensive
experience developing new medicines, including 25 years guiding
drug discovery, development and commercialization efforts at
ChemoCentryx, will be highly impactful as we continue to move
closer towards our goal of developing medicines with broad activity
for large populations of cancer patients.”
“I am delighted to join the Immuneering board at
this exciting time as the company advances its pipeline of
universal-RAS/RAF cancer medicines,” said Thomas J. Schall, Ph.D.
“I look forward to working with the senior leadership team and my
fellow board members to help guide Immuneering’s strategic
objectives with the aim of bringing important new treatment options
to cancer patients.”
Dr. Schall founded ChemoCentryx, Inc., a
publicly traded biotechnology company with an approved product, and
served as its President, Chief Executive Officer and Chairman for
25 years until its acquisition by Amgen for nearly $4 billion in
2022. From 1993 to 1997, Dr. Schall worked at the DNAX Research
Institute, a division of Schering-Plough Corporation. Prior to the
DNAX Research Institute, he was a scientist with Genentech, Inc.
Dr. Schall participated in some of the earliest discoveries of
chemokine system function and activities, and his laboratories have
been responsible for the discovery or co-discovery of a large
percentage of all known chemokine receptors. Dr. Schall received
his B.S. in biology from Northern Illinois University and his Ph.D.
in cancer biology from Stanford University.
About Immuneering
Corporation
Immuneering is a clinical-stage oncology company
seeking to develop and commercialize universal-RAS/RAF medicines
for broad populations of cancer patients with an initial aim to
develop a universal-RAS therapy. The Company aims to achieve
universal activity through deep cyclic inhibition of the MAPK
pathway, impacting cancer cells while sparing healthy cells.
Immuneering’s lead product candidate, IMM-1-104, is an oral,
once-daily deep cyclic inhibitor currently in a Phase 1/2a study in
patients with advanced solid tumors harboring RAS mutations.
IMM-6-415 is an oral, twice-daily deep cyclic inhibitor and will be
evaluated in a Phase 1/2a study in patients with advanced solid
tumors harboring RAS or RAF mutations. The company’s development
pipeline also includes several early-stage programs. For more
information, please visit www.immuneering.com.
Media Contact:Gina NugentNugent
Communications617-460-3579gina@nugentcommunications.com
Investor Contacts:Laurence WattsGilmartin
Group619-916-7620laurence@gilmartinir.com or
Kiki Patel, PharmDGilmartin
Group332-895-3225kiki@gilmartinir.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Apr 2024 to May 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From May 2023 to May 2024